{'fraction_non_alphanumeric': 0.033807829181494664, 'fraction_numerical': 0.014234875444839857, 'mean_word_length': 6.0375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The anti‐interleukin‐6 antibody siltuximab down‐regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study

Interleukin‐6 (IL‐6) is associated with prostate cancer morbidity. In several experimental models, IL‐6 has been reported to have anti‐apoptotic and pro‐angiogenic effects. Siltuximab (CNTO 328) is a monoclonal anti‐IL‐6 antibody which has been successfully applied in several models representing prostate cancer. This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer.